Merck Czech Republic made a net profit of CZK 68.6 mil under revenues of CZK 1,850 mil in 2015, up 96.7% and 2.88%, respectively, when compared to the last year. This translates into a net margin of 3.71%.
Historically, the firm’s net profit reached an all time high of CZK 68.6 mil in 2015 and an all time low of CZK 1.98 mil in 2008. Since 2010, the firm's net profit has increased 486% or 42.4% a year on average.
On the operating level, EBITDA reached CZK 95.9 mil, up 78.8% when compared to the previous year. Over the last five years, company's EBITDA has grown 31.0% a year on average.
As far as Merck Czech Republic's peers are concerned, Roche Czech Republic posted net and EBITDA margin of 0.936% and 3.84%, respectively in 2015, Bayer Czech Republic generated margins of 2.89% and 3.93% and Amgen Czech Republic's profit margin reached 5.93% on the net and 7.66% on the EBITDA level in 2015.